Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology
- 276 Downloads
Personalised oncology through mutational profiling of cancers requires the procurement of fresh frozen tumour samples for genomics applications. While primary cancers are often surgically excised and therefore yield such tissue, metastases in the setting of a known cancer diagnosis are not routinely sampled prior to systemic therapy. Our study aimed to determine the suitability of extracted nucleic acids for genomics applications using distant metastatic prostate cancer samples obtained via percutaneous or surgical biopsy. Patients with metastatic prostate cancer were recruited for image-guided biopsy of metastases. Patients undergoing surgical procedures for the complications of metastases were also recruited. Tissue samples were flash frozen and cryosectioned for histological examination. DNA and RNA were simultaneously extracted and genomic DNA hybridised onto SNP arrays for genome-wide copy number analysis. 37 samples of metastatic tissue from seven patients with prostate cancer were obtained. Five of these underwent image-guided biopsies whilst two had therapeutic surgical procedures performed. 22 biopsy samples were obtained across the image-guided biopsy patients with 80 % of samples being successfully processed for downstream analysis. Nucleic acid yield from these samples were satisfactory for genomics applications. Copy number analysis revealed a median estimated tumour purity of 53 % and all samples showed chromosomal abnormalities suggestive of malignancy. The procurement of osseous metastatic prostate cancer from live patients, including the use of image-guided biopsy, is safe and feasible. Sufficient tissue can be obtained in a manner such that extracted nucleic acids are suitable for genomics research.
KeywordsProstate cancer Metastasis Guided biopsy Genomics Biorepository
MKHH has been supported by scholarships from the Royal Australasian College of Surgeons, the National Health and Medical Research Council, Australia, and the Melville Hughes Scholarship, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne. GM is supported by NICTA. NICTA is funded by the Australian Government as represented by the Department of Broadband, Communications and the Digital Economy and the Australian Research Council through the ICT Centre of Excellence program. MK is supported by the Carlo Vaccari Scholarship. We gratefully acknowledge the Australian Genome Research Facility for providing genomics services, Associate Professor Kate Drummond for her assistance in procurement of some samples, and also the men who so kindly donated their metastatic tissues.
- 8.Diaz Z (2012) Quebec clinical research organization in cancer consortium. Feasibility and challenges of a biopsy-driven and biomarker discovery clinical trial in metastatic colorectal cancer to identify signatures of clinical resistance. ASCO Meeting Abstracts; 30 (15_suppl), e14108Google Scholar
- 9.Roychowdhury S, Iyer MK, Robinson DR, et al. (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111) 111ra21Google Scholar